Clinical studies of histone deacetylase inhibitors

Clin Cancer Res. 2009 Jun 15;15(12):3958-69. doi: 10.1158/1078-0432.CCR-08-2785. Epub 2009 Jun 9.

Abstract

Over the last 5 years, a plethora of histone deacetylase inhibitors (HDACi) have been evaluated in clinical trials. These drugs have in common the ability to hyperacetylate both histone and nonhistone targets, resulting in a variety of effects on cancer cells, their microenvironment, and immune responses. To date, responses with single agent HDACi have been predominantly observed in advanced hematologic malignancies including T-cell lymphoma, Hodgkin lymphoma, and myeloid malignancies. Therefore, in this review we focus upon hematologic malignancies. Generally HDACi are well tolerated with the most common acute toxicities being fatigue, gastrointestinal, and transient cytopenias. Of note, few patients have been treated for prolonged periods of time and little is known about long-term toxicities. The use of the biomarker of histone hyperacetylation has been useful as a guide to target specificity, but generally does not predict for response and the search for more clinically relevant biomarkers must continue.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / pharmacology
  • Antibiotics, Antineoplastic / therapeutic use*
  • Benzamides / administration & dosage
  • Benzamides / adverse effects
  • Benzamides / therapeutic use
  • Clinical Trials as Topic
  • Depsipeptides / administration & dosage
  • Depsipeptides / adverse effects
  • Depsipeptides / therapeutic use
  • Drug Therapy, Combination
  • Enzyme Inhibitors / adverse effects
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use*
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / pathology
  • Histone Deacetylase Inhibitors*
  • Humans
  • Hydroxamic Acids / administration & dosage
  • Hydroxamic Acids / adverse effects
  • Hydroxamic Acids / therapeutic use
  • Indoles
  • Panobinostat
  • Pyridines / administration & dosage
  • Pyridines / adverse effects
  • Pyridines / therapeutic use
  • Pyrimidines / administration & dosage
  • Pyrimidines / adverse effects
  • Pyrimidines / therapeutic use
  • Sulfonamides
  • Vorinostat

Substances

  • Antibiotics, Antineoplastic
  • Benzamides
  • Depsipeptides
  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Pyridines
  • Pyrimidines
  • Sulfonamides
  • entinostat
  • Vorinostat
  • Panobinostat
  • mocetinostat
  • romidepsin
  • belinostat